Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 10 2022 - 8:00AM
Business Wire
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will present at the
H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on
Wednesday, August 17, 2022:
Pre-Recorded Corporate Presentation Date: Wednesday,
August 17, 2022 Time: 7:00 AM ET
Panel Discussion - Unique Delivery Technology Platforms for
Better Compliance and Efficacy Date: Wednesday, August 17, 2022
Time: 11:00 AM ET
The management team will host investor meetings on Wednesday,
August 17th at the conference. Investors participating in the
conference who are interested in meeting with Ocular Therapeutix
management should contact their H.C. Wainwright representative.
A webcast of the pre-recorded corporate presentation and the
panel discussion can be accessed by visiting the Investors section
of the Company’s website at investors.ocutx.com and will remain
available for replay for 90 days.
About Ocular Therapeutix, Inc. Ocular Therapeutix, Inc.
is a biopharmaceutical company focused on the formulation,
development, and commercialization of innovative therapies for
diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s first commercial drug product, DEXTENZA®, is an
FDA-approved corticosteroid for the treatment of ocular
inflammation and pain following ophthalmic surgery and ocular
itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in Phase 1 clinical
trials for the treatment of wet AMD and other retinal diseases;
OTX-TIC (travoprost intracameral implant), currently in a Phase 2
clinical trial for the treatment of primary open-angle glaucoma or
ocular hypertension; and OTX-CSI (cyclosporine intracanalicular
insert) for the chronic treatment of dry eye disease and OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of
which have completed Phase 2 clinical trials. Ocular Therapeutix's
first product, ReSure® Sealant, is an FDA-approved device to
prevent wound leaks in corneal incisions following cataract
surgery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220810005126/en/
Investors Ocular Therapeutix Donald Notman Chief
Financial Officer dnotman@ocutx.com
or
ICR Westwicke Chris Brinzey, 339-970-2843 Managing Director
chris.brinzey@westwicke.com
Media Ocular Therapeutix Scott Corning Senior Vice
President, Commercial scorning@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Apr 2023 to Apr 2024